Pathology, Amyloid, Positron emission tomography, Alzheimer's disease and Internal medicine are his primary areas of study. His work carried out in the field of Pathology brings together such families of science as Episodic memory and Cognitive test. His Alzheimer's disease study combines topics in areas such as Dementia and Nuclear medicine.
Michael J. Pontecorvo connects Nuclear medicine with Amyloid pathology in his research. His Internal medicine research incorporates elements of Standardized uptake value, Cognition and Cardiology. His Amyloid β research includes themes of Radiology, Pet imaging, Neuropathology, Prospective cohort study and Autopsy.
His primary areas of investigation include Pathology, Amyloid, Nuclear medicine, Disease and Positron emission tomography. When carried out as part of a general Pathology research project, his work on Dementia, Autopsy, Dementia with Lewy bodies and Amyloid pet is frequently linked to work in Chemistry, therefore connecting diverse disciplines of study. Michael J. Pontecorvo combines subjects such as Radiology, Cognition and Atrophy with his study of Amyloid.
His work on Pet imaging is typically connected to Test retest reproducibility as part of general Nuclear medicine study, connecting several disciplines of science. In general Disease study, his work on Cognitive impairment and Solanezumab often relates to the realm of Clinical diagnosis, thereby connecting several areas of interest. His studies deal with areas such as Alzheimer's disease, Effective dose and Cognitive decline as well as Positron emission tomography.
His primary scientific interests are in Nuclear medicine, Pathology, Internal medicine, Disease and Dementia. His work in the fields of Nuclear medicine, such as Pet imaging, intersects with other areas such as Phase. His research in the fields of Autopsy and Amyloid overlaps with other disciplines such as Basal ganglia.
His research investigates the link between Disease and topics such as Cognition that cross with problems in National Adult Reading Test. His Dementia research is multidisciplinary, incorporating elements of Neuropathology and Pathological. His work in Neuropathology tackles topics such as Stage which are related to areas like Positron emission tomography.
Michael J. Pontecorvo spends much of his time researching Positron emission tomography, Nuclear medicine, Standardized uptake value, Alzheimer's disease and Dementia. His research brings together the fields of Psychiatry and Positron emission tomography. His Nuclear medicine research includes themes of Pittsburgh compound B, Magnetic resonance imaging, Brain size, Disease and Amyloid burden.
His Standardized uptake value study combines topics in areas such as Longitudinal study, Cardiology, Effects of sleep deprivation on cognitive performance, Cognition and Neuropsychological test. The study incorporates disciplines such as Volumetric magnetic resonance imaging, Atrophy, Cohort and Autopsy in addition to Alzheimer's disease. His Dementia study improves the overall literature in Internal medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Christopher M. Clark;Julie A. Schneider;Barry J. Bedell;Thomas G. Beach.
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Christopher M Clark;Michael J Pontecorvo;Thomas G Beach;Barry J Bedell.
Lancet Neurology (2012)
The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET
William E. Klunk;William E. Klunk;Robert A. Koeppe;Julie C. Price;Tammie L. Benzinger;Tammie L. Benzinger.
Alzheimers & Dementia (2015)
Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects
Abhinay D. Joshi;Michael J. Pontecorvo;Chrisopher M. Clark;Alan P. Carpenter.
The Journal of Nuclear Medicine (2012)
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Eric R. Siemers;Karen L. Sundell;Christopher Carlson;Michael Case.
Alzheimers & Dementia (2016)
Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods
Susan M. Landau;Susan M. Landau;Susan M. Landau;Christopher Breault;Abhinay D. Joshi;Michael Pontecorvo.
The Journal of Nuclear Medicine (2013)
Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease
Adam S. Fleisher;Kewei Chen;Xiaofen Liu;Auttawut Roontiva.
JAMA Neurology (2011)
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.
Susan M. Landau;Susan M. Landau;Ming Lu;Abhinay D. Joshi;Michael Pontecorvo.
Annals of Neurology (2013)
Individual differences in aging: Behavioral and neurobiological correlates
Alicja L. Markowska;William S. Stone;Donald K. Ingram;Jay Reynolds.
Neurobiology of Aging (1989)
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Michael J. Pontecorvo;Michael D. Devous;Michael Navitsky;Ming Lu.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: